TNF and lung adenocarcinoma: While angiogenesis inhibition was utilized as part of the regimen for some patients in the control cohort, this was a factor difficult to control for, as at the time bevacizumab was part of the standard first-line regimen at MSK for patients with lung adenocarcinoma (and so withholding it could not be mandated), though we have no a priori expectations that angiogenesis inhibition would directly affect TNF-α levels.